• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对癌症或良性肿瘤患者血清或尿液(或两者)中的组织多肽抗原进行初步评估。

A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms.

作者信息

Menendez-Botet C J, Oettgen H F, Pinsky C M, Schwartz M K

出版信息

Clin Chem. 1978 Jun;24(6):868-72.

PMID:657473
Abstract

We evaluated assays of Tissue Polypeptide Antigen in serum and urine, as an index to the presence of cancer. In the assay, serum, which is first absorbed with human albumin-labeled sheep erythrocytes, or untreated urine (diluted with an equal volume of TPA-free serum) is incubated with antibody specific to Tissue Polypeptide Antigen and then reacted with sheep erythrocytes labeled with Tissue Polypeptide Antigen. We found an increased concentration of Tissue Polypeptide Antigen in the serum of 378 of 513 (74%) and in the urine of 49 of 77 (64%) patients with cancer, as compared with 40/112 (36%) and 7/29 (24%), respectively, for individuals with benign neoplasms. Normal individuals were defined as those with less than 0.09 unit of the antigen per milliliter of specimen. Concentrations exceeding this were found in 2/67 (3%) sera and 6/56 (11%) urines from supposedly normal persons. Tissue Polypeptide Antigen was found in above-normal concentrations in patients with cancer, regardless of neoplasm type and extension, with a higher proportion of abnormal values in patients with distal metastases.

摘要

我们评估了血清和尿液中组织多肽抗原检测作为癌症存在指标的情况。在该检测中,首先用人类白蛋白标记的绵羊红细胞吸附的血清或未处理的尿液(用等体积不含组织多肽抗原的血清稀释)与组织多肽抗原特异性抗体孵育,然后与用组织多肽抗原标记的绵羊红细胞反应。我们发现,513例癌症患者中有378例(74%)血清中组织多肽抗原浓度升高,77例中有49例(64%)尿液中该抗原浓度升高,相比之下,良性肿瘤患者中分别为40/112(36%)和7/29(24%)。正常个体定义为每毫升标本中抗原含量低于0.09单位的个体。在假定正常的人的2/67(3%)份血清和6/56(11%)份尿液中发现浓度超过此值。无论肿瘤类型和分期如何,癌症患者中均发现组织多肽抗原浓度高于正常,远端转移患者中异常值比例更高。

相似文献

1
A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms.对癌症或良性肿瘤患者血清或尿液(或两者)中的组织多肽抗原进行初步评估。
Clin Chem. 1978 Jun;24(6):868-72.
2
[Preliminary results of the clinical use of TPA (tissue polypeptide antigen)].[组织多肽抗原(TPA)临床应用的初步结果]
Arch De Vecchi Anat Patol. 1983 Jul;65(2-3):301-13.
3
Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.组织多肽抗原(TPA)和癌胚抗原(CEA)在乳腺癌中的免疫细胞化学定位差异
Cancer Detect Prev. 1983;6(1-2):193-8.
4
Serum tissue polypeptide antigen (TPA) in thyroid cancer.甲状腺癌中的血清组织多肽抗原(TPA)
J Endocrinol Invest. 1984 Jun;7(3):249-52. doi: 10.1007/BF03348433.
5
Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance.癌胚抗原与组织多肽抗原联合应用于肿瘤治疗及监测
Cancer Detect Prev. 1983;6(1-2):51-9.
6
Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.支气管源性癌中的肿瘤标志物。组织多肽抗原相对于癌胚抗原和糖类抗原决定簇19-9的优势。
Cancer. 1987 Jul 1;60(1):42-50. doi: 10.1002/1097-0142(19870701)60:1<42::aid-cncr2820600109>3.0.co;2-3.
7
Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma.血清和组织中的癌胚抗原、铁蛋白及组织多肽抗原。与乳腺癌中受体含量的关系。
Cancer. 1986 Mar 1;57(5):917-22. doi: 10.1002/1097-0142(19860301)57:5<917::aid-cncr2820570506>3.0.co;2-m.
8
[Clinical evaluation of serum tissue polypeptide antigen (TPA) in patients with colo-rectal cancer].[血清组织多肽抗原(TPA)在结直肠癌患者中的临床评估]
Nihon Geka Hokan. 1984 Mar 1;53(2):433-6.
9
[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].[组织多肽抗原水平在肿瘤患者中的重要性。其与其他肿瘤标志物的相关性]
Rev Esp Oncol. 1984;31(3):409-14.
10
[Distribution and prognostic value of CEA and TPA in cancer of the lung].[癌胚抗原和组织多肽抗原在肺癌中的分布及预后价值]
Minerva Med. 1986 Mar 17;77(11):375-9.

引用本文的文献

1
Determination of TPA levels in breast cancer and controls.乳腺癌及对照样本中组织型纤溶酶原激活物(TPA)水平的测定。
Klin Wochenschr. 1983 May 2;61(9):461-8. doi: 10.1007/BF02664334.
2
Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer.血浆组织多肽抗原测定在膀胱尿路上皮癌诊断及随访中的意义
Urol Res. 1984;12(2):125-8. doi: 10.1007/BF00257178.
3
Serum tissue polypeptide antigen (TPA) in thyroid cancer.甲状腺癌中的血清组织多肽抗原(TPA)
J Endocrinol Invest. 1984 Jun;7(3):249-52. doi: 10.1007/BF03348433.
4
Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker.
EMBO J. 1984 Nov;3(11):2707-14. doi: 10.1002/j.1460-2075.1984.tb02198.x.
5
Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?第三届戈登·汉密尔顿-费尔利纪念讲座。肿瘤标志物——我们将何去何从?
Br J Cancer. 1983 Aug;48(2):167-75. doi: 10.1038/bjc.1983.172.
6
Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis.组织多肽抗原(TPA)在胰腺癌诊断中的应用
Br J Cancer. 1985 Nov;52(5):801-3. doi: 10.1038/bjc.1985.262.
7
Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?组织多肽抗原在诊断胰腺癌方面比血清癌胚抗原更准确吗?
J Clin Pathol. 1986 Jan;39(1):75-7. doi: 10.1136/jcp.39.1.75.
8
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.良性和恶性妇科疾病患者血清中六种肿瘤标志物的水平。
Arch Gynecol Obstet. 1988;243(2):61-8. doi: 10.1007/BF00932971.
9
Immunoradiometrical measurement of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) in pregnancy and at delivery.孕期及分娩时组织多肽抗原(TPA)和癌抗原125(CA125)的免疫放射测量法
Arch Gynecol Obstet. 1988;243(4):191-7. doi: 10.1007/BF00932267.
10
Urine-TPA (tissue polypeptide antigen), flow cytometry and cytology as markers for tumor invasiveness in urinary bladder carcinoma.尿组织多肽抗原(TPA)、流式细胞术及细胞学作为膀胱癌肿瘤侵袭性标志物的研究
Urol Res. 1989;17(5):269-72. doi: 10.1007/BF00262980.